Recent findings from over two dozen studies presented at the American Society of Clinical Oncology meeting in Chicago suggest that GLP-1 drugs, such as Ozempic and Wegovy, may offer protective effects against various cancers. These studies indicate that patients taking these medications have lower risks of developing cancer, reduced disease progression, and improved survival rates compared to those not using GLP-1s. Notably, a study involving over 12,000 patients found that GLP-1 users were 38% to 50% less likely to experience cancer metastasis, particularly in lung, breast, and colorectal cancers. Additionally, patients with type 2 diabetes and stage 3 kidney disease showed lower mortality rates and fewer cancer diagnoses. While researchers believe that the anti-inflammatory properties of GLP-1s may contribute to these benefits, they caution that most data comes from observational studies, which cannot definitively prove causation. Randomized trials are necessary to establish clear anti-cancer benefits, and some are already in planning stages.